Form 4: BioAge Labs Director Rekha Hemrajani Granted 22,000 Stock Options

BioAge Labs, Inc. Director Rekha Hemrajani was granted 22,000 stock options with an exercise price of $4.44, vesting on the earlier of the next annual meeting or one year from the grant date.

Summary

• Rekha Hemrajani, a Director of BioAge Labs, Inc. (BIOA), was granted 22,000 stock options on June 5, 2025.
• The options have an exercise price of $4.44 per share.
• The entire option award will vest on the earlier of the date of the next annual meeting of the Issuer's stockholders or the one-year anniversary of the grant date (June 5, 2026), contingent on Ms. Hemrajani's continued service to the Issuer.
• The options are exercisable and expire on June 4, 2035.
• Following this transaction, Ms. Hemrajani beneficially owns 22,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning management interests with shareholders and for retention, indicating stability in governance. It's a routine compensation event, not a major catalyst, hence a moderately positive score.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and retention.
• The options have a long expiration date (June 4, 2035), providing ample time for potential value appreciation.

Risks

• The value of the stock options is subject to the future performance of BioAge Labs, Inc.'s common stock.
• Vesting of the options is contingent upon the director's continued service to the Issuer.

Future Outlook

The stock options granted to Director Rekha Hemrajani are designed to incentivize her continued service and align her interests with the long-term performance of BioAge Labs, Inc. The options will vest on the earlier of the next annual meeting or one year from the grant date, subject to her continued service.

Industry Context

This Form 4 filing reports a standard equity compensation grant to a director, a common practice across industries, including biotechnology, to attract, retain, and incentivize key personnel by aligning their financial interests with shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Rekha Hemrajani, a Director of BioAge Labs, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's incentives with shareholder interests, potentially leading to better long-term performance. It also represents a potential future dilution if options are exercised, though this is standard for equity compensation.
• Employees: No direct impact on general employees is noted, but it reinforces the company's commitment to equity-based incentives for key personnel.

Next Steps

• The stock options will vest on the earlier of the next annual meeting of BioAge Labs' stockholders or the one-year anniversary of the grant date (June 5, 2026), subject to continued service.

Key Dates

Recommendation

Keywords

BioAge Labs, BIOA, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Rekha Hemrajani, Biotechnology, Pharmaceuticals